SCHEMBL4587958

SCHEMBL4587958

NC1(C[PH](=O)O)CCCC1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823934 0.98 TSHR (0.34) TSHRCYP2C19
SCHEMBL6828006 0.98 TSHR (0.34) TSHRCYP2C19
SCHEMBL6827747 0.95
SCHEMBL6827326 0.90
SCHEMBL8732601 0.68
Phosphonic Acid SCHEMBL10622793 0.65 TSHR (0.40) TSHRCYP2C19
SCHEMBL6829273 0.65
SCHEMBL229077 0.64
SCHEMBL289131 0.62 CYP1A2 (0.52) TSHRCYP2C19
SCHEMBL2790764 0.62 TSHR (0.37) TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150038464-A1 METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2015-02-05 US disclosed
WO-2013126088-A1 METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2013-08-29 WO disclosed
EP-1458669-A4 NEUOROLOGICALLY-ACTIVE COMPOUNDS UNIV SYDNEY (AU) 2008-10-29 EP disclosed
EP-1458669-A1 NEUOROLOGICALLY-ACTIVE COMPOUNDS THE UNIVERSITY OF SYDNEY (AU) 2004-09-22 EP disclosed
WO-2003045897-A1 NEOROLOGICALLY-ACTIVE COMPOUNDS UNIVERSITY OF SYDNEY (AU) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038464-A1 METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION GRM5, GRM1, GRIK5 TSHR 818/4885CYP2C19 4136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.